The rapid evolution of Generative AI (GenAI) technologies has the potential to accelerate drug discovery, improve patient engagement, streamline operations, and drive significant advancements in personalized medicine.
Explore how USDM leverages remote audits with virtual tools like AR, VR, and cloud systems to streamline vendor qualification and regulatory compliance.
This white paper addresses the lack of regulatory guidelines for AI and introduces an interim path forward to realize the value of AI for life sciences organizations.
